Janssen Announced First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma At ASCO
Portfolio Pulse from Charles Gross
Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, announced positive results from the Phase 1b RedirecTT-1 study of TECVAYLI and talquetamab, showing a 96% overall response rate in patients with relapsed or refractory multiple myeloma. The data was presented at the 2023 ASCO Annual Meeting.
June 03, 2023 | 6:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Janssen, a Johnson & Johnson subsidiary, announced positive results from a Phase 1b study of TECVAYLI and talquetamab, showing a 96% response rate in multiple myeloma patients.
The positive results from the Phase 1b study indicate that the combination of TECVAYLI and talquetamab has the potential to be an effective treatment for multiple myeloma patients. This could lead to increased demand for the drugs and potentially boost Johnson & Johnson's revenues in the future. As a result, the stock price is likely to go up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100